Spherical nucleic acid tlr9 agonists
AssigneeExicure, Inc.
InventorsBart Anderson, Subbarao Nallagatla, Richard Kang, Ekambar Kandimalla
Life of this patent
Estimating the term…
Abstract
Aspects of the invention relate to compositions of spherical nucleic acids (SNAs) composed of a liposome or lipoplex complex having an oligonucleotide shell with CpG oligonucleotides positioned on the exterior of the liposome or lipoplex. The invention also relates to methods of treating subjects and of inducing cytokine expression in a subject using the compositions described herein.
Claims21
-64. (canceled)
A method of treating a subject having cancer or at risk of having cancer, comprising:
- administering to a subject an immune system agonist of OX40 or OX40L, and a spherical nucleic acid (SNA) to treat the subject having cancer or at risk of having cancer, wherein the SNA comprises a lipid nanoparticle having an oligonucleotide shell comprised of CpG oligonucleotides positioned on the exterior of the lipid nanoparticle.
A method of treating a subject having cancer or at risk of having cancer, comprising:
- administering to a subject an immune system agonist of OX40 or OX40L, an anti-PD-1 antibody, and a spherical nucleic acid (SNA) to treat the subject having cancer or at risk of having cancer, wherein the SNA comprises a lipid nanoparticle having an oligonucleotide shell comprised of CpG oligonucleotides positioned on the exterior of the lipid nanoparticle, such that the CpG oligonucleotides are oriented radially outwards, wherein the CpG oligonucleotides comprise the sequence 5′-T*C*G*T*C*G*T*T*T*T*G*T*C*G*T*T*T*T*G*T*C*G*T*T-3′ (SEQ ID NO:
- 2), wherein the CpG oligonucleotides are each conjugated to a cholesterol via a linker comprising two hexaethylene glycols, wherein the cholesterol anchors the CpG oligonucleotides to the lipids of the lipid nanoparticle, and wherein each internucleoside linkage of the CpG oligonucleotides is an internucleoside phosphorothioate linkage.
Dependencies are inferred from the claim text.